ERBB2 and breast carcinoma: In particular, it has been observed that, whilst few patients with HER2-positive advanced gastric cancer exhibit primary resistance to trastuzumab, all acquire resistance after a relatively short period of time (median PFS 6.7 months) [17], as already observed in HER2-positive breast cancer patients.